Faculty

As cancer therapeutics evolve beyond traditional chemotherapy and immune checkpoint inhibitors, oncologists and endocrinologists are encountering an expanding spectrum of endocrine-related adverse events. This Meet the Professor session will explore the diverse landscape of endocrine toxicities associated with novel cancer therapies, including targeted therapies and newer immunotherapeutic agents. The session will provide a comprehensive overview of endocrine complications arising from non-ICI cancer treatments through case-based discussions, participants will learn to recognize early warning signs, understand pathophysiologic mechanisms, and develop practical management strategies for these increasingly common complications.

This session is ideal for endocrinologists, advanced practice providers, and trainees seeking to enhance their understandingHere of this rapidly evolving field. Participants will leave with practical tools for identifying and managing these complex toxicities in their clinical practice.

Objectives:

1. Identify toxicities associated with targeted cancer therapies and newer agents
2. Understand screening and monitoring strategies for patients receiving these treatments

Onco Endocrinology SIG Meet the Professor: Complications of Novel Non-Immunotherapy Cancer Therapies. Beyond Checkpoint Inhibitors

Afreen Idris Shariff, MD

Duke University

Faculty

Randol Kennedy, MD

DUKE UNIVERSITY MEDICAL CENTER